Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel Free PRCT Stock Alerts

PROCEPT BioRobotics (PRCT) Financials

PROCEPT BioRobotics logo
$22.76 +1.39 (+6.50%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for PROCEPT BioRobotics

Annual Income Statements for PROCEPT BioRobotics

This table shows PROCEPT BioRobotics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -53 -60 -87 -106 -91 -96
Consolidated Net Income / (Loss)		 -53 -60 -87 -106 -91 -96
Net Income / (Loss) Continuing Operations		 -53 -60 -87 -106 -91 -96
Total Pre-Tax Income 		-53 -60 -87 -106 -91 -95
Total Operating Income		 -48 -54 -81 -109 -97 -104
Total Gross Profit		 -1.26 16 37 71 137 196
Total Revenue		 7.72 34 75 136 224 308
Operating Revenue		 - 34 75 136 224 308
Total Cost of Revenue		 8.97 19 38 65 87 112
Operating Cost of Revenue		 8.97 19 38 65 87 112
Total Operating Expenses		 47 70 118 180 234 300
Selling, General & Admin Expense		 30 51 89 132 171 229
Research & Development Expense		 16 19 29 48 62 71
Total Other Income / (Expense), net		 -5.22 -5.69 -6.43 3.35 5.57 8.48
Interest Expense		 5.26 5.81 8.44 4.00 4.18 3.59
Other Income / (Expense), net		 0.04 0.12 2.01 7.35 9.75 12
Income Tax Expense		 - - - 0.08 0.37 0.19
Basic Earnings per Share		 ($14.47) ($3.63) ($1.96) ($2.24) ($1.75) ($1.72)
Weighted Average Basic Shares Outstanding		 3.66M 16.48M 44.40M 47.26M 52.13M 55.54M
Diluted Earnings per Share		 ($14.47) ($3.63) ($1.96) ($2.24) ($1.75) ($1.72)
Weighted Average Diluted Shares Outstanding		 3.66M 16.48M 44.40M 47.26M 52.13M 55.54M
Weighted Average Basic & Diluted Shares Outstanding		 - 43.99M 44.87M 50.96M 54.82M 56.39M

Quarterly Income Statements for PROCEPT BioRobotics

This table shows PROCEPT BioRobotics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -28 -26 -26 -21 -19 -25 -20 -21 -30 -32 -27
Consolidated Net Income / (Loss)		 -28 -26 -26 -21 -19 -25 -20 -21 -30 -32 -27
Net Income / (Loss) Continuing Operations		 -28 -26 -26 -21 -19 -25 -20 -21 -30 -32 -27
Total Pre-Tax Income 		-28 -26 -26 -21 -19 -25 -19 -21 -30 -32 -27
Total Operating Income		 -30 -28 -27 -22 -20 -27 -22 -23 -31 -33 -27
Total Gross Profit		 21 25 31 37 44 44 52 54 46 54 62
Total Revenue		 44 45 53 58 68 69 79 83 76 83 94
Operating Revenue		 44 45 53 58 68 69 79 83 76 83 94
Total Cost of Revenue		 22 20 22 21 25 25 27 29 30 29 32
Operating Cost of Revenue		 22 20 22 21 25 25 27 29 30 29 32
Total Operating Expenses		 51 53 58 59 63 72 74 77 77 87 90
Selling, General & Admin Expense		 36 40 41 43 48 55 56 59 58 65 70
Research & Development Expense		 14 13 18 17 15 16 18 18 19 21 20
Total Other Income / (Expense), net		 2.05 1.69 1.20 1.45 0.85 2.65 2.75 1.78 1.38 0.93 0.62
Interest Expense		 1.13 1.05 1.03 1.14 0.97 0.88 0.90 0.92 0.90 0.82 0.84
Other Income / (Expense), net		 3.18 2.74 2.23 2.59 1.82 3.53 3.64 2.70 2.28 1.74 1.47
Income Tax Expense		 - - - - - -0.05 0.14 - - -0.04 0.09
Basic Earnings per Share		 ($0.54) ($0.51) ($0.50) ($0.40) ($0.34) ($0.45) ($0.35) ($0.38) ($0.54) ($0.56) ($0.47)
Weighted Average Basic Shares Outstanding		 47.26M 51.01M 51.62M 52.01M 52.13M 54.92M 55.45M 55.73M 55.54M 56.51M 57.07M
Diluted Earnings per Share		 ($0.54) ($0.51) ($0.50) ($0.40) ($0.34) ($0.45) ($0.35) ($0.38) ($0.54) ($0.56) ($0.47)
Weighted Average Diluted Shares Outstanding		 47.26M 51.01M 51.62M 52.01M 52.13M 54.92M 55.45M 55.73M 55.54M 56.51M 57.07M
Weighted Average Basic & Diluted Shares Outstanding		 50.96M 51.42M 51.93M 52.18M 54.82M 55.33M 55.64M 55.88M 56.39M 56.92M 57.27M

Annual Cash Flow Statements for PROCEPT BioRobotics

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 58 204 -79 35 77 -47
Net Cash From Operating Activities		 -48 -57 -80 -108 -99 -49
Net Cash From Continuing Operating Activities		 -48 -57 -80 -108 -99 -49
Net Income / (Loss) Continuing Operations		 -53 -60 -87 -106 -91 -96
Consolidated Net Income / (Loss)		 -53 -60 -87 -106 -91 -96
Depreciation Expense		 2.86 - 2.84 3.81 5.23 6.39
Non-Cash Adjustments To Reconcile Net Income		 2.30 3.90 15 25 37 48
Changes in Operating Assets and Liabilities, net		 -0.48 -4.71 -11 -31 -50 -7.84
Net Cash From Investing Activities		 -0.23 -0.59 -2.65 -25 -4.41 -9.36
Net Cash From Continuing Investing Activities		 -0.23 -0.59 -2.65 -25 -4.41 -9.36
Purchase of Property, Plant & Equipment		 -0.23 -0.59 -2.65 -25 -4.41 -9.36
Net Cash From Financing Activities		 107 262 3.61 168 180 11
Net Cash From Continuing Financing Activities		 107 262 3.61 168 180 11
Issuance of Debt		 25 0.00 54 3.61 4.53 6.36
Issuance of Common Equity		 0.00 172 0.00 162 165 0.00
Other Financing Activities, net		 5.60 5.04 1.01 2.48 11 4.83
Effect of Exchange Rate Changes		 - - - 0.00 0.00 -0.07
Cash Interest Paid		 3.97 4.75 4.29 4.06 3.97 3.46

Quarterly Cash Flow Statements for PROCEPT BioRobotics

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -31 -32 -11 -17 137 -18 -13 -8.44 -7.78 -41 -18
Net Cash From Operating Activities		 -25 -32 -16 -19 -32 -17 -15 -6.64 -10 -38 -19
Net Cash From Continuing Operating Activities		 -25 -32 -16 -19 -32 -17 -15 -6.64 -10 -38 -19
Net Income / (Loss) Continuing Operations		 -28 -26 -26 -21 -19 -25 -20 -21 -30 -32 -27
Consolidated Net Income / (Loss)		 -28 -26 -26 -21 -19 -25 -20 -21 -30 -32 -27
Depreciation Expense		 1.32 1.18 1.27 1.33 1.45 1.48 1.59 1.62 1.71 1.74 1.99
Non-Cash Adjustments To Reconcile Net Income		 4.87 8.76 8.80 9.25 7.38 11 12 15 9.79 14 15
Changes in Operating Assets and Liabilities, net		 -3.48 -16 -0.18 -8.40 -22 -4.33 -9.50 -2.03 8.02 -22 -9.73
Net Cash From Investing Activities		 -8.72 -1.95 -1.04 -0.25 -1.17 -1.84 -2.80 -2.87 -1.85 -2.91 -2.95
Net Cash From Continuing Investing Activities		 -8.72 -1.95 -1.04 -0.25 -1.17 -1.84 -2.80 -2.87 -1.85 -2.91 -2.95
Purchase of Property, Plant & Equipment		 -8.72 -1.95 -1.04 -0.25 -1.17 -1.84 -2.80 -2.87 -1.85 -2.91 -2.95
Net Cash From Financing Activities		 2.87 2.59 5.30 1.72 171 1.30 4.38 1.08 4.44 0.22 4.50
Net Cash From Continuing Financing Activities		 2.87 2.59 5.30 1.72 171 1.30 4.38 1.08 4.44 0.22 4.50
Other Financing Activities, net		 0.97 2.59 3.17 1.72 3.60 1.30 0.87 1.08 1.58 0.22 0.18
Effect of Exchange Rate Changes		 - - - - - 0.00 - -0.01 -0.04 -0.04 -0.02
Cash Interest Paid		 1.00 1.00 1.03 1.01 0.92 0.89 0.87 0.88 0.83 0.80 0.79

Annual Balance Sheets for PROCEPT BioRobotics

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 126 337 309 405 534 508
Total Current Assets		 110 326 273 351 482 450
Cash & Equivalents		 100 304 222 257 334 287
Accounts Receivable		 1.55 4.46 15 48 83 84
Inventories, net		 6.92 13 29 40 56 71
Prepaid Expenses		 1.65 4.24 6.18 5.21 8.45 9.65
Plant, Property, & Equipment, net		 8.27 5.05 8.66 29 27 30
Total Noncurrent Assets		 7.44 5.81 28 25 25 27
Goodwill		 2.02 1.75 1.48 1.20 0.93 0.71
Other Noncurrent Operating Assets		 5.42 4.06 27 24 25 27
Total Liabilities & Shareholders' Equity		 126 337 309 405 534 508
Total Liabilities		 65 70 112 124 132 142
Total Current Liabilities		 15 16 35 46 53 66
Accounts Payable		 1.24 2.03 9.39 13 10 17
Accrued Expenses		 4.64 6.48 13 17 22 23
Current Deferred Revenue		 0.23 1.03 2.86 5.66 9.57 13
Other Current Liabilities		 3.86 6.71 9.60 9.89 12 12
Total Noncurrent Liabilities		 50 54 77 78 79 76
Long-Term Debt		 44 50 51 51 51 52
Other Noncurrent Operating Liabilities		 6.08 3.69 26 27 27 25
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -183 267 197 281 402 366
Total Preferred & Common Equity		 -183 267 197 281 402 366
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -183 267 197 281 402 366
Common Stock		 19 529 546 735 948 1,007
Retained Earnings		 -202 -262 -349 -455 -546 -642
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.05 -0.01 0.08 0.11 0.04

Quarterly Balance Sheets for PROCEPT BioRobotics

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 284 272 421 383 374 374 519 513 512 487 479
Total Current Assets		 246 230 369 329 322 323 466 458 455 428 420
Cash & Equivalents		 181 150 287 226 214 197 316 303 294 246 228
Accounts Receivable		 21 33 35 56 59 69 79 81 85 96 108
Inventories, net		 39 43 42 42 44 51 62 67 67 78 77
Prepaid Expenses		 4.26 3.74 3.98 5.91 5.02 6.32 7.99 7.50 9.25 8.47 7.70
Plant, Property, & Equipment, net		 12 16 27 28 28 27 28 29 30 32 32
Total Noncurrent Assets		 27 26 25 25 25 25 25 26 27 27 27
Goodwill		 1.41 1.34 1.27 1.14 1.07 1.00 0.86 0.80 0.73 0.64 0.57
Other Noncurrent Operating Assets		 26 25 24 24 24 24 25 26 26 27 27
Total Liabilities & Shareholders' Equity		 284 272 421 383 374 374 519 513 512 487 479
Total Liabilities		 111 117 122 119 123 133 130 127 131 139 139
Total Current Liabilities		 33 36 41 39 43 54 52 50 54 64 64
Accounts Payable		 10 10 14 10 9.95 15 15 12 11 19 15
Accrued Expenses		 7.41 9.95 13 11 15 19 15 16 22 18 20
Current Deferred Revenue		 3.94 4.72 5.01 5.86 6.55 7.99 9.80 9.89 11 14 14
Other Current Liabilities		 7.81 11 9.49 9.54 11 12 10 12 10 10 15
Total Noncurrent Liabilities		 79 81 80 80 80 79 78 78 77 76 75
Long-Term Debt		 51 51 51 51 51 51 51 52 52 52 52
Other Noncurrent Operating Liabilities		 28 29 29 29 28 28 27 26 26 24 23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 173 156 299 264 252 241 389 386 380 348 340
Total Preferred & Common Equity		 173 156 299 264 252 241 389 386 380 348 340
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 173 156 299 264 252 241 389 386 380 348 340
Common Stock		 550 558 726 744 758 768 960 976 992 1,021 1,040
Retained Earnings		 -377 -402 -427 -481 -506 -527 -571 -590 -612 -673 -700
Accumulated Other Comprehensive Income / (Loss)		 0.02 -0.01 -0.01 0.11 -0.00 -0.02 0.22 -0.14 0.04 -0.02 0.02

Annual Metrics And Ratios for PROCEPT BioRobotics

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 346.72% 117.60% 81.55% 64.84% 37.22%
EBITDA Growth		 0.00% -12.96% -49.59% -29.29% 16.41% -4.63%
EBIT Growth		 0.00% -13.16% -45.65% -29.46% 14.40% -5.68%
NOPAT Growth		 0.00% -13.31% -49.04% -35.24% 11.50% -7.50%
Net Income Growth		 0.00% -12.89% -45.61% -21.51% 13.68% -4.55%
EPS Growth		 0.00% 74.91% 46.01% -14.29% 21.88% 1.71%
Operating Cash Flow Growth		 0.00% -18.60% -40.20% -34.36% 8.14% 50.63%
Free Cash Flow Firm Growth		 0.00% 0.00% -69.63% -81.09% 10.28% 25.74%
Invested Capital Growth		 0.00% 30.52% 100.78% 191.90% 60.24% 9.18%
Revenue Q/Q Growth		 0.00% 0.00% 22.22% 17.02% 12.34% 2.72%
EBITDA Q/Q Growth		 0.00% 0.00% -6.01% 1.48% 14.34% -14.20%
EBIT Q/Q Growth		 0.00% 0.00% -9.98% -2.34% 8.87% -13.44%
NOPAT Q/Q Growth		 0.00% 0.00% -11.32% -4.32% 9.25% -12.24%
Net Income Q/Q Growth		 0.00% 0.00% -12.70% 0.63% 8.64% -12.99%
EPS Q/Q Growth		 0.00% 0.00% -229.80% 3.86% 10.26% -13.16%
Operating Cash Flow Q/Q Growth		 0.00% -5.58% -12.13% 0.35% -8.29% 31.05%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -12.84% -4.75% 21.35%
Invested Capital Q/Q Growth		 0.00% 0.00% 3.80% 19.22% 25.10% -4.78%
Profitability Metrics		 - - - - - -
Gross Margin		 -16.26% 46.02% 49.44% 52.17% 61.07% 63.70%
EBITDA Margin		 -581.81% -147.13% -101.14% -72.03% -36.52% -27.72%
Operating Margin		 -619.44% -157.12% -107.61% -80.16% -43.04% -33.71%
EBIT Margin		 -618.87% -156.77% -104.93% -74.82% -38.86% -29.80%
Profit (Net Income) Margin		 -687.04% -173.62% -116.18% -77.76% -40.72% -31.02%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.20%
Interest Burden Percent		 111.02% 110.75% 110.72% 103.92% 104.80% 103.91%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -341.86% -336.08% -294.12% -152.05% -69.42% -57.94%
ROIC Less NNEP Spread (ROIC-NNEP)		 -303.64% -321.72% -279.73% -136.42% -59.68% -49.10%
Return on Net Nonoperating Assets (RNNOA)		 254.89% 299.59% 256.57% 107.73% 42.65% 33.06%
Return on Equity (ROE)		 -86.97% -36.49% -37.55% -44.32% -26.77% -24.89%
Cash Return on Invested Capital (CROIC)		 0.00% -362.56% -361.13% -249.98% -115.72% -66.72%
Operating Return on Assets (OROA)		 -37.91% -23.35% -24.36% -28.54% -18.58% -17.62%
Return on Assets (ROA)		 -42.09% -25.85% -26.97% -29.66% -19.48% -18.34%
Return on Common Equity (ROCE)		 260.94% -9.37% -37.55% -44.32% -26.77% -24.89%
Return on Equity Simple (ROE_SIMPLE)		 28.99% -22.41% -44.22% -37.72% -22.73% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -38 -57 -76 -68 -73
NOPAT Margin		 -433.61% -109.98% -75.33% -56.11% -30.12% -23.60%
Net Nonoperating Expense Percent (NNEP)		 -38.22% -14.36% -14.40% -15.63% -9.74% -8.85%
Return On Investment Capital (ROIC_SIMPLE)		 - - -22.76% -23.01% -14.91% -17.41%
Cost of Revenue to Revenue		 116.26% 53.98% 50.56% 47.83% 38.93% 36.30%
SG&A Expenses to Revenue		 392.28% 148.05% 118.42% 96.76% 76.35% 74.28%
R&D to Revenue		 210.90% 55.10% 38.63% 35.57% 27.75% 23.14%
Operating Expenses to Revenue		 603.17% 203.14% 157.05% 132.33% 104.10% 97.41%
Earnings before Interest and Taxes (EBIT)		 -48 -54 -79 -102 -87 -92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -51 -76 -98 -82 -85
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 4.07 9.43 7.54 10.45 4.80
Price to Tangible Book Value (P/TBV)		 0.00 4.10 9.50 7.57 10.47 4.81
Price to Revenue (P/Rev)		 17.82 31.56 24.76 15.54 18.72 5.71
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 33.73 65.25 65.74 25.52 32.67 11.63
Enterprise Value to Revenue (EV/Rev)		 42.79 24.18 22.48 14.03 17.46 4.94
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.80 0.19 0.26 0.18 0.13 0.14
Long-Term Debt to Equity		 0.73 0.19 0.26 0.18 0.13 0.14
Financial Leverage		 -0.84 -0.93 -0.92 -0.79 -0.71 -0.67
Leverage Ratio		 2.07 1.41 1.39 1.49 1.37 1.36
Compound Leverage Factor		 2.29 1.56 1.54 1.55 1.44 1.41
Debt to Total Capital		 44.54% 15.77% 20.63% 15.46% 11.35% 12.36%
Short-Term Debt to Total Capital		 4.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 40.40% 15.77% 20.63% 15.46% 11.35% 12.36%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 221.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -166.39% 84.23% 79.37% 84.54% 88.65% 87.64%
Debt to EBITDA		 -1.09 -0.99 -0.68 -0.52 -0.63 -0.60
Net Debt to EBITDA		 1.14 5.01 2.26 2.10 3.44 2.75
Long-Term Debt to EBITDA		 -0.99 -0.99 -0.68 -0.52 -0.63 -0.60
Debt to NOPAT		 -1.46 -1.32 -0.91 -0.67 -0.76 -0.71
Net Debt to NOPAT		 1.53 6.71 3.03 2.69 4.17 3.23
Long-Term Debt to NOPAT		 -1.33 -1.32 -0.91 -0.67 -0.76 -0.71
Altman Z-Score		 -1.25 8.92 8.67 9.08 18.54 6.57
Noncontrolling Interest Sharing Ratio		 400.02% 74.33% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 7.59 20.08 7.73 7.63 9.07 6.85
Quick Ratio		 7.00 19.01 6.72 6.65 7.85 5.62
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -41 -69 -126 -113 -84
Operating Cash Flow to CapEx		 -20,748.07% -9,684.80% -3,029.85% -428.48% -2,250.24% -523.57%
Free Cash Flow to Firm to Interest Expense		 0.00 -7.04 -8.22 -31.45 -26.94 -23.35
Operating Cash Flow to Interest Expense		 -9.19 -9.87 -9.52 -27.03 -23.71 -13.66
Operating Cash Flow Less CapEx to Interest Expense		 -9.23 -9.97 -9.84 -33.34 -24.77 -16.27
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.06 0.15 0.23 0.38 0.48 0.59
Accounts Receivable Turnover		 4.98 11.47 7.60 4.28 3.40 3.69
Inventory Turnover		 1.30 1.85 1.82 1.91 1.82 1.76
Fixed Asset Turnover		 0.93 5.18 10.95 7.28 8.10 10.79
Accounts Payable Turnover		 7.24 11.38 6.64 5.69 7.43 8.19
Days Sales Outstanding (DSO)		 73.26 31.83 48.02 85.29 107.20 98.95
Days Inventory Outstanding (DIO)		 281.68 196.85 200.60 191.34 200.30 207.04
Days Payable Outstanding (DPO)		 50.45 32.06 54.95 64.13 49.14 44.58
Cash Conversion Cycle (CCC)		 304.50 196.62 193.66 212.51 258.37 261.41
Capital & Investment Metrics		 - - - - - -
Invested Capital		 9.79 13 26 75 120 131
Invested Capital Turnover		 0.79 3.06 3.90 2.71 2.30 2.46
Increase / (Decrease) in Invested Capital		 0.00 2.99 13 49 45 11
Enterprise Value (EV)		 330 834 1,686 1,911 3,920 1,523
Market Capitalization		 138 1,088 1,858 2,116 4,202 1,758
Book Value per Share		 ($49.93) $6.14 $4.41 $5.56 $7.71 $6.55
Tangible Book Value per Share		 ($50.48) $6.10 $4.37 $5.54 $7.69 $6.53
Total Capital		 110 317 248 332 454 417
Total Debt		 49 50 51 51 51 52
Total Long-Term Debt		 44 50 51 51 51 52
Net Debt		 -51 -254 -171 -206 -282 -235
Capital Expenditures (CapEx)		 0.23 0.59 2.65 25 4.41 9.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.15 5.61 15 47 95 98
Debt-free Net Working Capital (DFNWC)		 100 310 237 305 429 385
Net Working Capital (NWC)		 96 310 237 305 429 385
Net Nonoperating Expense (NNE)		 20 22 31 29 24 23
Net Nonoperating Obligations (NNO)		 -51 -254 -171 -206 -282 -235
Total Depreciation and Amortization (D&A)		 2.86 3.32 2.84 3.81 5.23 6.39
Debt-free, Cash-free Net Working Capital to Revenue		 1.96% 16.28% 19.60% 34.82% 42.31% 31.84%
Debt-free Net Working Capital to Revenue		 1,299.48% 899.05% 316.39% 223.69% 190.96% 124.84%
Net Working Capital to Revenue		 1,240.51% 899.05% 316.39% 223.69% 190.96% 124.84%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.63) ($1.96) ($2.24) ($1.75) ($1.72)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 16.48M 44.40M 47.26M 52.13M 55.54M
Adjusted Diluted Earnings per Share		 $0.00 ($3.63) ($1.96) ($2.24) ($1.75) ($1.72)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 16.48M 44.40M 47.26M 52.13M 55.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 43.99M 44.87M 50.96M 54.82M 56.39M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -38 -57 -76 -68 -73
Normalized NOPAT Margin		 -433.61% -109.98% -75.33% -56.11% -30.12% -23.60%
Pre Tax Income Margin		 -687.04% -173.62% -116.18% -77.76% -40.72% -30.96%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -9.08 -9.30 -9.33 -25.51 -20.85 -25.60
NOPAT to Interest Expense		 -6.36 -6.53 -6.69 -19.13 -16.16 -20.27
EBIT Less CapEx to Interest Expense		 -9.12 -9.40 -9.64 -31.82 -21.90 -28.21
NOPAT Less CapEx to Interest Expense		 -6.40 -6.63 -7.01 -25.44 -17.22 -22.88
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for PROCEPT BioRobotics

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 56,390,196.00 56,918,844.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 56,390,196.00 56,918,844.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.56 -0.47
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 83.29% 82.51% 61.17% 66.29% 56.57% 55.28% 48.41% 42.76% 11.94% 20.20% 19.34%
EBITDA Growth		 -7.18% 11.48% 1.48% 17.93% 34.43% 5.66% 26.72% -1.99% -68.38% -29.85% -41.14%
EBIT Growth		 -9.70% 9.73% -1.13% 15.97% 32.20% 4.22% 24.04% -3.32% -64.17% -29.10% -39.78%
NOPAT Growth		 -18.05% 2.57% -4.69% 12.43% 33.32% 0.76% 17.29% -3.41% -57.48% -18.84% -23.44%
Net Income Growth		 2.36% 8.87% -1.35% 14.82% 31.45% 4.70% 23.60% -2.08% -58.28% -27.90% -37.20%
EPS Growth		 14.29% 19.05% 10.71% 21.57% 37.04% 11.76% 30.00% 5.00% -58.82% -24.44% -34.29%
Operating Cash Flow Growth		 1.51% 10.14% 44.47% 0.75% -30.65% 47.41% 4.40% 64.71% 68.12% -124.54% -27.97%
Free Cash Flow Firm Growth		 -129.96% -39.60% 2.55% 12.89% 15.76% 17.14% -19.32% -18.67% 44.40% 3.06% 20.65%
Invested Capital Growth		 191.90% 100.68% 57.10% 52.70% 60.24% 38.11% 51.09% 43.45% 9.18% 23.43% 21.74%
Revenue Q/Q Growth		 24.16% 2.20% 19.79% 9.40% 16.90% 1.36% 14.49% 5.23% -8.33% 8.84% 13.67%
EBITDA Q/Q Growth		 -11.15% 10.06% 1.69% 20.67% 11.20% -36.21% 23.63% -10.41% -43.33% -7.67% 17.82%
EBIT Q/Q Growth		 -11.77% 5.57% 1.27% 19.36% 9.82% -33.39% 21.70% -9.68% -40.35% -7.31% 16.00%
NOPAT Q/Q Growth		 -15.42% 6.46% 2.97% 16.40% 12.11% -39.21% 19.13% -4.52% -33.84% -5.05% 16.00%
Net Income Q/Q Growth		 -11.71% 5.63% 1.28% 18.15% 10.10% -31.19% 20.86% -9.36% -39.40% -6.00% 15.10%
EPS Q/Q Growth		 -5.88% 5.56% 1.96% 20.00% 15.00% -32.35% 22.22% -8.57% -42.11% -3.70% 16.07%
Operating Cash Flow Q/Q Growth		 -30.88% -30.22% 51.26% -19.47% -72.29% 47.58% 11.41% 55.89% -55.64% -269.20% 49.51%
Free Cash Flow Firm Q/Q Growth		 -24.81% 6.62% 21.63% 4.63% -20.70% 8.15% -12.85% 5.15% 43.45% -60.16% 7.63%
Invested Capital Q/Q Growth		 19.22% 22.27% -2.68% 7.64% 25.10% 5.39% 6.46% 2.20% -4.78% 19.14% 5.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 48.77% 56.21% 59.01% 63.24% 64.00% 63.85% 65.35% 64.81% 60.63% 64.89% 66.01%
EBITDA Margin		 -57.51% -53.27% -43.72% -31.70% -24.08% -32.37% -21.59% -22.65% -35.42% -35.04% -25.33%
Operating Margin		 -67.83% -62.08% -50.28% -38.42% -28.89% -39.67% -28.02% -27.83% -40.64% -39.22% -28.98%
EBIT Margin		 -60.53% -55.93% -46.10% -33.98% -26.21% -34.50% -23.60% -24.59% -37.65% -37.13% -27.43%
Profit (Net Income) Margin		 -63.11% -58.28% -48.03% -35.93% -27.63% -35.77% -24.73% -25.70% -39.07% -38.06% -28.42%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.64% 99.86% 100.35%
Interest Burden Percent		 104.26% 104.19% 104.19% 105.75% 105.42% 103.68% 104.79% 104.48% 103.11% 102.65% 103.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -128.65% -99.05% -85.26% -67.74% -46.60% -63.48% -48.22% -50.06% -69.84% -62.60% -45.86%
ROIC Less NNEP Spread (ROIC-NNEP)		 -125.04% -94.65% -80.03% -64.98% -44.52% -60.94% -46.27% -47.39% -66.70% -58.72% -42.27%
Return on Net Nonoperating Assets (RNNOA)		 98.74% 64.96% 51.41% 45.90% 31.82% 40.60% 30.03% 29.59% 44.91% 36.21% 24.89%
Return on Equity (ROE)		 -29.92% -34.10% -33.85% -21.84% -14.77% -22.88% -18.19% -20.47% -24.93% -26.39% -20.98%
Cash Return on Invested Capital (CROIC)		 -249.98% -177.66% -149.70% -135.63% -115.72% -93.93% -98.12% -91.18% -66.72% -75.00% -73.19%
Operating Return on Assets (OROA)		 -23.09% -26.20% -25.17% -17.08% -12.54% -19.05% -14.62% -16.65% -22.26% -23.76% -18.65%
Return on Assets (ROA)		 -24.08% -27.30% -26.22% -18.06% -13.22% -19.75% -15.32% -17.40% -23.10% -24.35% -19.32%
Return on Common Equity (ROCE)		 -29.92% -34.10% -33.85% -21.84% -14.77% -22.88% -18.19% -20.47% -24.93% -26.39% -20.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -39.15% -41.19% -41.48% 0.00% -23.18% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -19 -19 -16 -14 -19 -16 -16 -22 -23 -19
NOPAT Margin		 -47.48% -43.45% -35.20% -26.90% -20.22% -27.77% -19.62% -19.48% -28.45% -27.46% -20.29%
Net Nonoperating Expense Percent (NNEP)		 -3.61% -4.40% -5.23% -2.76% -2.07% -2.54% -1.96% -2.67% -3.14% -3.88% -3.60%
Return On Investment Capital (ROIC_SIMPLE)		 -6.23% - - - -3.04% -4.34% -3.55% -3.76% -5.20% -5.68% -4.89%
Cost of Revenue to Revenue		 51.23% 43.79% 40.99% 36.76% 36.00% 36.15% 34.65% 35.19% 39.37% 35.11% 33.99%
SG&A Expenses to Revenue		 83.33% 88.91% 76.49% 73.14% 70.81% 79.81% 71.11% 70.82% 76.32% 78.29% 73.72%
R&D to Revenue		 33.26% 29.38% 32.80% 28.52% 22.08% 23.72% 22.27% 21.83% 24.95% 25.82% 21.27%
Operating Expenses to Revenue		 116.60% 118.29% 109.29% 101.66% 92.89% 103.52% 93.37% 92.64% 101.27% 104.12% 95.00%
Earnings before Interest and Taxes (EBIT)		 -26 -25 -25 -20 -18 -24 -19 -20 -29 -31 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -24 -23 -19 -16 -22 -17 -19 -27 -29 -24
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7.54 9.45 12.48 17.25 10.45 8.21 8.26 5.22 4.80 4.06 3.78
Price to Tangible Book Value (P/TBV)		 7.57 9.49 12.53 17.32 10.47 8.23 8.28 5.23 4.81 4.06 3.79
Price to Revenue (P/Rev)		 15.54 15.96 17.79 20.82 18.72 12.82 11.59 6.62 5.71 4.38 3.81
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 25.52 25.38 33.44 41.87 32.67 23.18 21.81 12.67 11.63 7.81 6.77
Enterprise Value to Revenue (EV/Rev)		 14.03 14.86 16.87 20.09 17.46 11.77 10.68 5.81 4.94 3.78 3.29
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.18 0.20 0.20 0.21 0.13 0.14 0.13 0.14 0.14 0.16 0.15
Long-Term Debt to Equity		 0.18 0.19 0.20 0.21 0.13 0.13 0.13 0.14 0.14 0.15 0.15
Financial Leverage		 -0.79 -0.69 -0.64 -0.71 -0.71 -0.67 -0.65 -0.62 -0.67 -0.62 -0.59
Leverage Ratio		 1.49 1.53 1.59 1.47 1.37 1.38 1.39 1.43 1.36 1.37 1.37
Compound Leverage Factor		 1.56 1.59 1.65 1.56 1.45 1.43 1.46 1.49 1.40 1.40 1.41
Debt to Total Capital		 15.46% 16.74% 16.95% 17.58% 11.35% 12.08% 11.78% 11.94% 12.36% 13.45% 13.20%
Short-Term Debt to Total Capital		 0.00% 0.54% 0.00% 0.00% 0.00% 0.45% 0.00% 0.00% 0.00% 0.59% 0.00%
Long-Term Debt to Total Capital		 15.46% 16.20% 16.95% 17.58% 11.35% 11.63% 11.78% 11.94% 12.36% 12.86% 13.20%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 84.54% 83.26% 83.05% 82.42% 88.65% 87.92% 88.22% 88.06% 87.64% 86.55% 86.80%
Debt to EBITDA		 -0.52 -0.53 -0.52 -0.54 -0.63 -0.66 -0.69 -0.69 -0.60 -0.59 -0.52
Net Debt to EBITDA		 2.10 1.74 1.64 1.52 3.44 3.26 3.38 3.25 2.75 2.08 1.78
Long-Term Debt to EBITDA		 -0.52 -0.52 -0.52 -0.54 -0.63 -0.64 -0.69 -0.69 -0.60 -0.56 -0.52
Debt to NOPAT		 -0.67 -0.70 -0.67 -0.69 -0.76 -0.79 -0.80 -0.80 -0.71 -0.71 -0.65
Net Debt to NOPAT		 2.69 2.27 2.12 1.95 4.17 3.89 3.91 3.75 3.23 2.51 2.20
Long-Term Debt to NOPAT		 -0.67 -0.68 -0.67 -0.69 -0.76 -0.76 -0.80 -0.80 -0.71 -0.68 -0.65
Altman Z-Score		 9.70 11.95 14.63 18.03 18.97 14.46 14.79 8.80 6.98 5.49 4.91
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.63 8.52 7.51 6.02 9.07 8.95 9.21 8.44 6.85 6.73 6.55
Quick Ratio		 6.65 7.29 6.37 4.95 7.85 7.60 7.71 7.03 5.62 5.37 5.23
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -70 -65 -51 -49 -59 -54 -61 -58 -33 -52 -48
Operating Cash Flow to CapEx		 -284.49% -1,659.10% -1,508.72% -7,642.28% -2,759.03% -924.84% -536.87% -231.35% -558.22% -1,308.41% -651.91%
Free Cash Flow to Firm to Interest Expense		 -62.14 -62.47 -49.67 -42.80 -60.78 -61.68 -68.21 -63.00 -36.58 -64.11 -57.53
Operating Cash Flow to Interest Expense		 -22.04 -30.90 -15.28 -16.49 -33.43 -19.36 -16.81 -7.22 -11.54 -46.61 -22.86
Operating Cash Flow Less CapEx to Interest Expense		 -29.78 -32.76 -16.29 -16.71 -34.64 -21.46 -19.94 -10.34 -13.61 -50.17 -26.37
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.38 0.47 0.55 0.50 0.48 0.55 0.62 0.68 0.59 0.64 0.68
Accounts Receivable Turnover		 4.28 4.08 3.83 3.86 3.40 3.68 3.94 3.91 3.69 3.67 3.58
Inventory Turnover		 1.91 1.81 1.85 1.83 1.82 1.79 1.78 1.81 1.76 1.66 1.68
Fixed Asset Turnover		 7.28 7.73 8.02 7.45 8.10 8.80 9.77 10.59 10.79 10.76 11.16
Accounts Payable Turnover		 5.69 7.12 8.00 5.94 7.43 7.46 9.06 8.11 8.19 6.89 8.99
Days Sales Outstanding (DSO)		 85.29 89.57 95.18 94.67 107.20 99.15 92.75 93.44 98.95 99.55 101.94
Days Inventory Outstanding (DIO)		 191.34 202.11 197.50 199.41 200.30 204.22 205.55 201.80 207.04 220.03 217.88
Days Payable Outstanding (DPO)		 64.13 51.25 45.63 61.47 49.14 48.94 40.28 44.98 44.58 52.98 40.60
Cash Conversion Cycle (CCC)		 212.51 240.43 247.05 232.61 258.37 254.44 258.02 250.26 261.41 266.59 279.21
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 75 92 89 96 120 126 135 138 131 156 164
Invested Capital Turnover		 2.71 2.28 2.42 2.52 2.30 2.29 2.46 2.57 2.46 2.28 2.26
Increase / (Decrease) in Invested Capital		 49 46 32 33 45 35 46 42 11 30 29
Enterprise Value (EV)		 1,911 2,323 2,979 4,015 3,920 2,931 2,936 1,743 1,523 1,219 1,109
Market Capitalization		 2,116 2,496 3,142 4,161 4,202 3,194 3,187 1,986 1,758 1,410 1,285
Book Value per Share		 $5.56 $5.18 $4.88 $4.64 $7.71 $7.10 $6.97 $6.84 $6.55 $6.17 $5.97
Tangible Book Value per Share		 $5.54 $5.15 $4.86 $4.63 $7.69 $7.08 $6.96 $6.82 $6.53 $6.15 $5.96
Total Capital		 332 317 303 293 454 443 437 432 417 402 392
Total Debt		 51 53 51 51 51 53 52 52 52 54 52
Total Long-Term Debt		 51 51 51 51 51 51 52 52 52 52 52
Net Debt		 -206 -173 -163 -145 -282 -263 -251 -243 -235 -192 -176
Capital Expenditures (CapEx)		 8.72 1.95 1.04 0.25 1.17 1.84 2.80 2.87 1.85 2.91 2.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 47 67 65 73 95 100 106 107 98 121 128
Debt-free Net Working Capital (DFNWC)		 305 292 279 269 429 416 408 401 385 367 356
Net Working Capital (NWC)		 305 291 279 269 429 414 408 401 385 364 356
Net Nonoperating Expense (NNE)		 6.81 6.60 6.85 5.28 5.06 5.53 4.05 5.18 8.12 8.81 7.69
Net Nonoperating Obligations (NNO)		 -206 -173 -163 -145 -282 -263 -251 -243 -235 -192 -176
Total Depreciation and Amortization (D&A)		 1.32 1.18 1.27 1.33 1.45 1.48 1.59 1.62 1.71 1.74 1.99
Debt-free, Cash-free Net Working Capital to Revenue		 34.82% 42.64% 36.79% 36.32% 42.31% 39.94% 38.42% 35.54% 31.84% 37.61% 38.00%
Debt-free Net Working Capital to Revenue		 223.69% 186.94% 158.03% 134.77% 190.96% 166.87% 148.51% 133.66% 124.84% 113.89% 105.56%
Net Working Capital to Revenue		 223.69% 185.85% 158.03% 134.77% 190.96% 166.07% 148.51% 133.66% 124.84% 113.16% 105.56%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.54) ($0.51) ($0.50) ($0.40) ($0.34) ($0.45) ($0.35) ($0.38) ($0.54) ($0.56) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 47.26M 51.01M 51.62M 52.01M 52.13M 54.92M 55.45M 55.73M 55.54M 56.51M 57.07M
Adjusted Diluted Earnings per Share		 ($0.54) ($0.51) ($0.50) ($0.40) ($0.34) ($0.45) ($0.35) ($0.38) ($0.54) ($0.56) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding		 47.26M 51.01M 51.62M 52.01M 52.13M 54.92M 55.45M 55.73M 55.54M 56.51M 57.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.96M 51.42M 51.93M 52.18M 54.82M 55.33M 55.64M 55.88M 56.39M 56.92M 57.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -19 -19 -16 -14 -19 -16 -16 -22 -23 -19
Normalized NOPAT Margin		 -47.48% -43.45% -35.20% -26.90% -20.22% -27.77% -19.62% -19.48% -28.45% -27.46% -20.29%
Pre Tax Income Margin		 -63.11% -58.28% -48.03% -35.93% -27.63% -35.77% -24.73% -25.70% -38.83% -38.11% -28.33%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -23.45 -23.84 -23.88 -17.40 -18.46 -27.21 -20.87 -22.30 -32.14 -37.73 -30.79
NOPAT to Interest Expense		 -18.39 -18.52 -18.23 -13.77 -14.24 -21.90 -17.35 -17.67 -24.28 -27.90 -22.77
EBIT Less CapEx to Interest Expense		 -31.20 -25.70 -24.89 -17.61 -19.67 -29.30 -24.01 -25.42 -34.20 -41.29 -34.30
NOPAT Less CapEx to Interest Expense		 -26.14 -20.38 -19.25 -13.99 -15.45 -23.99 -20.49 -20.79 -26.34 -31.46 -26.28
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

PROCEPT BioRobotics has delivered strong top-line growth, but profitability and cash generation remain significant challenges. Revenue increased from $33.1 million in Q2 2023 to $94.5 million in Q2 2026, representing growth of approximately 185%. However, the company continues to report substantial operating and net losses, while cash has declined sharply from its early-2025 peak.

  • Rapid revenue growth: Quarterly revenue rose from $23.8 million in Q4 2022 to $94.5 million in Q2 2026. On a year-over-year basis, Q2 2026 revenue increased approximately 19% from $79.2 million in Q2 2025.
  • Gross margin expansion: Gross margin improved to approximately 66.0% in Q2 2026, compared with 65.3% in Q2 2025 and 55.5% in Q2 2023. This indicates that revenue growth is increasingly producing gross profit.
  • Sequential improvement in operating results: The operating loss narrowed to $27.4 million in Q2 2026 from $32.6 million in Q1 2026. The quarterly net loss also improved to $26.9 million from $31.6 million.
  • Strong liquidity position: PROCEPT reported $227.9 million of cash and equivalents at June 30, 2026, compared with $64.2 million of total current liabilities. The company also held substantially more cash than its approximately $51.7 million of long-term debt.
  • Improving operating cash flow compared with Q1 2026: Cash used in operating activities declined to $19.3 million in Q2 2026 from $38.1 million in Q1 2026. While still negative, the improvement provides some evidence of better near-term cash management.
  • Working-capital investment is increasing: Accounts receivable rose to $107.6 million and inventory stood at $77.1 million in Q2 2026, up considerably from $33.2 million and $42.6 million, respectively, in Q2 2023. These balances may support growth, but they also tie up cash and require monitoring.
  • Continued investment in operations: Capital expenditures were approximately $3.0 million in Q2 2026, broadly consistent with recent quarters. Net property, plant and equipment increased to $31.8 million from $28.6 million in Q2 2024, suggesting ongoing investment in infrastructure and capacity.
  • Debt levels have been relatively stable: Long-term debt remained near $51.7 million in Q2 2026, little changed from approximately $51.2 million in Q2 2023. This limits the immediate increase in leverage, although the company continues to pay interest while operating at a loss.
  • Persistent unprofitability: PROCEPT has reported a net loss in every quarterly income statement provided. The Q2 2026 net loss was $26.9 million, compared with $19.6 million in Q2 2025 and $25.3 million in Q2 2023.
  • Operating expenses continue to exceed gross profit: Selling, general and administrative expense was $69.7 million and research and development expense was $20.1 million in Q2 2026. Together, these expenses consumed approximately $89.8 million, exceeding the $62.4 million gross profit and producing a $27.4 million operating loss.
  • Ongoing cash burn: Operating cash flow was negative in every period supplied, including $19.3 million of cash used in Q2 2026. Cash declined from $316.2 million at March 31, 2025, to $227.9 million at June 30, 2026, a reduction of approximately 28%.
  • Share dilution has been substantial: Weighted-average basic shares increased from 44.5 million in Q2 2023 to 57.1 million in Q2 2026. Additional equity financing can extend the company’s cash runway, but it reduces existing shareholders’ ownership percentage and raises the burden on future earnings growth.
  • Accumulated losses remain large: Retained earnings were negative $700.1 million at June 30, 2026, compared with negative $402.4 million in Q2 2023. This reflects the company’s long history of losses and highlights the need for a path toward sustainable profitability.

Overall, the statements show a company with strong commercial momentum and improving gross economics, but revenue growth has not yet translated into profitability or positive operating cash flow. Investors should focus on whether PROCEPT can control selling and administrative spending, reduce quarterly cash burn, and eventually convert its expanding revenue base into positive earnings without relying heavily on additional equity issuance.

09/04/26 06:21 PM ETAI Generated. May Contain Errors.

PROCEPT BioRobotics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PROCEPT BioRobotics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

PROCEPT BioRobotics' net income appears to be on an upward trend, with a most recent value of -$95.57 million in 2025, rising from -$53.02 million in 2020. The previous period was -$91.41 million in 2024. See PROCEPT BioRobotics' forecast for analyst expectations on what's next for the company.

PROCEPT BioRobotics' total operating income in 2025 was -$103.86 million, based on the following breakdown:
  • Total Gross Profit: $196.23 million
  • Total Operating Expenses: $300.09 million

Over the last 5 years, PROCEPT BioRobotics' total revenue changed from $7.72 million in 2020 to $308.05 million in 2025, a change of 3,891.9%.

PROCEPT BioRobotics' total liabilities were at $142.21 million at the end of 2025, a 7.9% increase from 2024, and a 118.7% increase since 2020.

In the past 5 years, PROCEPT BioRobotics' cash and equivalents has ranged from $100.13 million in 2020 to $333.73 million in 2024, and is currently $286.50 million as of their latest financial filing in 2025.

Over the last 5 years, PROCEPT BioRobotics' book value per share changed from -49.93 in 2020 to 6.55 in 2025, a change of -113.1%.


Related Companies

Financial statements for NASDAQ:PRCT last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Wall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)
The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...
Weiss Ratings | Sponsoredtc pixel
This Overlooked Fund Turns AI Stocks Into Weekly Income
A small fund pays investors weekly income from AI stocks that don't pay dividends on their own. Chief Incom...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel